Physician profile
Ira Harmon
NPI 1366460032
$2,087.70
in general payments reported to CMS, 2019-2025
10 companies · $26.94 in 2025
The $26.94 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.46 · 2020: $68.31 · 2021: $399 · 2022: $479 · 2023: $648 · 2024: $450 · 2025: $26.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.23 |
| Education | $124.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,320.49 | 2021-2024 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $234.52 | 2023-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $217.70 | 2021-2024 | Rayaldee |
| Amgen INC. | $72.02 | 2020-2022 | |
| Horizon Therapeutics Plc | $66.86 | 2020-2022 | |
| Travere Therapeutics, INC. | $50.38 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $45.78 | 2022-2023 | Acthar |
| Fresenius USA Marketing, INC. | $38.41 | 2019-2023 | Velphoro |
| Ardelyx, INC. | $22.07 | 2023 | Ibsrela |
| Calliditas Therapeutics US INC. | $19.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.